Clesrovimab
drug drugOn this page
Also known as Mk-1654
Summary
Clesrovimab (CHEMBL4297783) is a phase-3 clinical-stage antibody; indicated across 1 condition including respiratory syncytial virus infectious disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297783 |
| Name | Clesrovimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Clesrovimab, Mk-1654, MK-1654, CLESROVIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| respiratory syncytial virus infectious disease | 3 | MONDO:0001577 | EFO:1001413 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04767373 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) |
| NCT04938830 | PHASE3 | COMPLETED | Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) |
| NCT03524118 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) |
| NCT04086472 | PHASE2 | COMPLETED | Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: respiratory syncytial virus infectious disease